Metastatic deaths in retinoblastoma patients treated with intraarterial chemotherapy (ophthalmic artery chemosurgery) worldwide

Ophthalmic artery chemosurgery [OAC, intra-arterial chemotherapy (IAC)] was introduced in 2006 as treatment modality for intraocular retinoblastoma. The purpose of this commentary is to retrospectively review the incidence of metastatic deaths in retinoblastoma patients treated with OAC worldwide ov...

Full description

Saved in:
Bibliographic Details
Published in:International journal of retina and vitreous 2017-10, Vol.3 (1), p.40-40, Article 40
Main Authors: Abramson, David H, Shields, Carol L, Jabbour, Pascal, Teixeira, Luiz Fernando, Fonseca, José Roberto Falco, Marques, Marcio Chaves Pedro, Munier, Francis L, Puccinelli, Francesco, Hadjistilianou, Theodora, Bracco, Sandra, Chantada, Guillermo, Ceciliano, Alejandro, Gobin, Y Pierre
Format: Article
Language:English
Subjects:
Cancer
Carotid arteries
Chemotherapy
Intra-arterial (intrarterial) chemotherapy (IAC)
Medical prognosis
Melphalan
Metastasis
Metastatic death
Ophthalmic artery chemosurgery (OAC)
Patients
Radiation therapy
Retina
Retinoblastoma
Retinoblastoma (Rb)
Tumors
Veins & arteries
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Ophthalmic artery chemosurgery [OAC, intra-arterial chemotherapy (IAC)] was introduced in 2006 as treatment modality for intraocular retinoblastoma. The purpose of this commentary is to retrospectively review the incidence of metastatic deaths in retinoblastoma patients treated with OAC worldwide over a 10 year period. Retrospective data regarding metastatic deaths was collected from six international retinoblastoma centers (New York City USA, Philadelphia USA, Sao Paulo Brazil, Siena Italy, Lausanne Switzerland and Buenos Aires Argentina). All retinoblastoma patients from these centers (naive and recurrent, unilateral and bilateral) treated with OAC/IAC since 2006 have been included in this study. Data regarding number of patients, number of OAC/IAC infusions, number unilateral and bilateral, number treated for naive disease or salvage and number of metastatic deaths have been assessed. Over a 10-year period of time 1139 patients received OAC/IAC for 4396 infusions. At last follow-up there were only three metastatic deaths (all treated in Buenos Aires). The current survey assessed the recorded risk of metastatic deaths in six retinoblastoma centers worldwide in children with retinoblastoma (unilateral or bilateral) treated with OAC/IAC as primary or secondary therapy. Overall, the observed risk for metastatic deaths from retinoblastoma was
ISSN:2056-9920
2056-9920
DOI:10.1186/s40942-017-0093-8